

Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

1 Guideline

Venous thromboembolism - reducing the risk (full update)

2 List of modelling questions

Review question by scope area	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective hip replacement?
Population	People admitted to hospital for elective total hip replacement surgery
Interventions and comparators considered for inclusion	<ol style="list-style-type: none"> 1. LMWH (standard dose, standard duration)+ anti-embolism stockings (AES) 2. LMWH (standard dose, extended duration)+ AES 3. Fondaparinux+ AES 4. Foot pump + AES 5. IPCD 6. AES (above knee) 7. Foot pump 8. AES 9. LMWH (standard dose, standard duration) 10. LMWH (standard dose, extended duration) 11. Aspirin (standard duration) 12. LMWH (standard dose, standard duration) + Aspirin (extended duration) 13. Dabigatran 14. Apixaban 15. Rivaroxaban 16. No prophylaxis
Perspective	NHS and PSS
Outcomes	Costs QALYs
Type of analysis	Cost-utility analysis (CUA)
Issues to note	
Review question by scope area	What is the effectiveness of different pharmacological and mechanical prophylaxis strategies (alone or in combination) for people undergoing elective knee replacement?
Population	People admitted to hospital for elective total knee replacement surgery
Interventions and comparators considered for	<ol style="list-style-type: none"> 1. LMWH (standard dose, standard duration)+ anti-embolism stockings (AES) 2. Fondaparinux+ AES 3. Foot pump + AES

4.0.04 DOC Economic Plan

inclusion	<ol style="list-style-type: none">4. IPCD5. Foot pump6. AES7. LMWH (standard dose, standard duration)8. LMWH (standard dose, extended duration)9. Aspirin10. Dabigatran11. Apixaban12. Rivaroxaban13. No prophylaxis
Perspective	NHS and PSS
Outcomes	Costs QALYs
Type of analysis	Cost-utility analysis (CUA)
Issues to note	